| Literature DB >> 36226268 |
Fang Fang1, Yanjie Cao1, Keyan Chen1, Xingjie Su1, Yanxiu Qi1, Di Zhang1, Hongwei Liu1.
Abstract
In order to solve some problems of subhealth and high chronic diseases, the diagnosis and treatment of value-added diabetic retinopathy are studied. In particular, diabetes, a high chronic disease, poses a great threat to people's health. With the continuous improvement of national health awareness, the medical field also begins to pay more attention to the diagnosis and treatment of value-added diabetic retinopathy. In order to improve the long-term treatment of value-added diabetic retinopathy through intelligent medical monitoring and systematic scientific efficacy analysis and evaluation, the purpose of this study is to explore how to effectively achieve the meta-analysis of long-term efficacy of proliferative diabetic retinopathy through intelligent medical treatment. Through the study of diabetic retinopathy, the system can help doctors to achieve unlimited further signs of parameter acquisition and transmission and build more mature after treatment of the results of the monitoring platform. At the same time, a conclusion based on vitrectomy was proposed to effectively improve the surgical efficacy of patients with proliferative diabetic retinopathy.Entities:
Mesh:
Year: 2022 PMID: 36226268 PMCID: PMC9525783 DOI: 10.1155/2022/6545553
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
Figure 1Overall block diagram of the intelligent monitoring system.
Comparison of wireless communication technical parameters.
| Wireless communication technology | The communication distance | Transmission rate | Power consumption (send/receive) | The sensitivity | Spectrum |
|---|---|---|---|---|---|
| Bluetooth | About 10 m | 1 Mbps | 300 mA/20 mA | −106 dBm | 2.4 GHz |
| WiFi | 30–150 m | 54 Mbps | 350 mA/70 mA | −92 dB m | 2.4 GHz |
| ZigBee | 30–75 m | 20–250 kbps | 35 mA/26 mA | −100 dBm | 2.4 GHz |
| LoRa | 2–15 km | 0.2–37. 5 kbps | 120 mA/10 mA | −142 dBm | <1 GHz |
Figure 2Datagram format.
Figure 3Principle of PTT measurement by ECG + pulse signal.
Figure 4Principle of measuring PTT by two pulse wave signals.
Figure 5Preoperative and postoperative visual acuity distribution of PDR patients.
Influence of preoperative diabetic course on the postoperative visual acuity improvement rate.
| Vision improvement | No improvement in vision | In total | |
|---|---|---|---|
| <5 years | 9(81.8) | 2(18.2) | 11(100.0) |
| 6∼11 years | 11(61.1) | 7(38.9) | 18(100.0) |
| >11 years | 22(68.8) | 10(31.3) | 32(100.0) |
| In total | 42(68.9) | 19(31.1) | 61(100.0) |
Influence of preoperative PDR stage on postoperative visual acuity improvement rate.
| Vision improvement | No vision improvement | In total | |
|---|---|---|---|
| Stage IV | 14(93.3) | 1(6.7) | 15(100.0) |
| Stage V | 12(70.6) | 5(29.4) | 17(100.0) |
| Stage VI | 16(55.2) | 13(44.8) | 29(100.0) |
| In total | 42(68.9) | 19(31.1) | 61(100.0) |
Postoperative visual acuity improvement rate of different vitreous fillers.
| The unfilled group | Perfluoropropane filled group | Silicone oil filling group | |
|---|---|---|---|
| Vision improvement (number of eyes) | 20 | 7 | 15 |
| No vision improvement (number of eyes) | 2 | 4 | 13 |
| Visual acuity improvement rate | 90.9% | 63.6% | 53.6% |
Relationship between preoperative PRP and postoperative visual acuity improvement rate.
| Vision improvement | No vision improvement | In total | |
|---|---|---|---|
| PRP was performed. | 13(61.9) | 8(38.1) | 21(100.0) |
| No PRP | 29(72.5) | 11(27.5) | 40(100.0) |
| In total | 42(68.9) | 19(31.3) | 61(100.0) |